What is the appropriate anticoagulation regimen for a 77-year-old man with hypothyroidism on levothyroxine and hypertension treated with diltiazem, valsartan, and hydrochlorothiazide who has new bilateral pulmonary emboli and lower-extremity deep vein thromboses?

Anticoagulation for Acute Bilateral Pulmonary Emboli and DVT

Start therapeutic anticoagulation immediately with either a direct oral anticoagulant (DOAC) or weight-based unfractionated heparin bridged to warfarin, with DOACs preferred for their superior safety profile and convenience in this 77-year-old patient. 1, 2, 3

Initial Anticoagulation Regimen

First-Line: Direct Oral Anticoagulants (DOACs)

DOACs are strongly preferred over warfarin for acute VTE treatment in patients without cancer, severe renal impairment (CrCl <30 mL/min), or antiphospholipid syndrome. 2, 3

Specific DOAC dosing options for acute PE/DVT: 1, 4

• Rivaroxaban: 15 mg orally twice daily with food for 21 days, then 20 mg once daily with food 1
• Apixaban: 10 mg orally twice daily for 7 days, then 5 mg twice daily 1, 4
• Dabigatran: Requires 5-10 days of parenteral anticoagulation first, then 150 mg twice daily (or 110 mg twice daily if age ≥80 years) 4
• Edoxaban: Requires 5-10 days of parenteral anticoagulation first, then 60 mg once daily (30 mg if CrCl 15-50 mL/min or weight ≤60 kg) 4

Alternative: Unfractionated Heparin Bridged to Warfarin

If DOACs are contraindicated or unavailable, use weight-based IV heparin: 5

• Initial bolus: 80 units/kg IV 6, 5
• Maintenance infusion: 18 units/kg/hour 6, 5
• Target aPTT: 1.5-2.5 × control (approximately 60-85 seconds) 6, 5
• First aPTT check: 4-6 hours after starting infusion 6, 5
• After dose adjustments: Recheck aPTT 6-10 hours later 6, 5
• Once therapeutic: Daily aPTT monitoring 6, 5

Warfarin overlap: 6, 2

• Start warfarin 5-10 mg daily on day 1 or 2 of heparin 6
• Continue heparin for minimum 5 days AND until INR ≥2.0 on two consecutive measurements 6, 2
• Target INR: 2.0-3.0 (goal 2.5) 6, 2

Duration of Anticoagulation

For this first unprovoked VTE (bilateral PE + DVT), treat with therapeutic anticoagulation for at least 3 months, then reassess for extended therapy. 2, 3

After 3 months, strongly consider extended (indefinite) anticoagulation if bleeding risk is low to moderate, as unprovoked VTE carries high recurrence risk. 2, 3

• Low bleeding risk: Extended anticoagulation recommended 2
• Moderate bleeding risk: Extended anticoagulation suggested 2
• High bleeding risk: Stop at 3 months 2

For extended therapy beyond 6 months, reduced-dose DOACs are acceptable alternatives: 1

• Rivaroxaban 10 mg daily (instead of 20 mg) 1
• Apixaban 2.5 mg twice daily (instead of 5 mg) 1

Critical Drug Interactions in This Patient

Levothyroxine and Anticoagulation

Levothyroxine increases the anticoagulant effect of warfarin; if warfarin is chosen, monitor INR more frequently and anticipate dose reductions as thyroid status normalizes. 7

• Heparin can transiently increase free T4 by displacing thyroid hormone from binding proteins, but this does not require levothyroxine dose adjustment 7
• DOACs have no significant interaction with levothyroxine and are therefore preferred in this patient 7

Diltiazem and Anticoagulation

Diltiazem is a moderate CYP3A4 inhibitor that significantly increases levels of rivaroxaban, apixaban, and edoxaban. 8

• If using rivaroxaban with diltiazem: Consider limiting diltiazem to 240 mg/day and monitoring closely for bleeding 8
• If using apixaban or edoxaban: Use standard dosing but monitor for bleeding complications 8
• Dabigatran is not metabolized by CYP3A4 and has no interaction with diltiazem 8
• Diltiazem does not affect warfarin metabolism 8

Valsartan and HCTZ

No clinically significant interactions with any anticoagulant. These medications can be continued without dose adjustment.

Monitoring and Follow-Up

Assess renal function before starting any DOAC, as all require dose adjustment or are contraindicated with severe renal impairment (CrCl <30 mL/min). 4, 3

Reassess anticoagulation duration at 3 months, considering: 2, 3

• Bleeding events during initial treatment
• Patient preference and adherence
• Fall risk and functional status (important at age 77)
• Presence of any occult malignancy (consider age-appropriate cancer screening)

Common Pitfalls to Avoid

Do not use subclinical hypothyroidism as a reason to avoid anticoagulation—this patient requires full therapeutic anticoagulation regardless of thyroid status. 9

Do not underdose anticoagulation due to advanced age alone—the mortality benefit of treating bilateral PE far outweighs bleeding risk in most 77-year-olds. 10, 3

Do not stop heparin before INR is therapeutic for at least 24 hours if using warfarin—premature discontinuation increases recurrent PE risk. 6, 5

Do not forget to recheck renal function postoperatively or during acute illness, as changes may require DOAC dose adjustment. 4

Given the diltiazem interaction, dabigatran may be the safest DOAC choice in this specific patient, though it requires parenteral lead-in. 4, 8